Market Closed -
Sao Paulo
04:07:00 2024-07-16 pm EDT
|
5-day change
|
1st Jan Change
|
12.29
BRL
|
+20.65%
|
|
+2.85%
|
-25.11%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
6,530
|
4,681
|
2,916
|
2,184
|
-
|
-
|
Enterprise Value (EV)
1 |
5,982
|
4,317
|
3,079
|
2,394
|
2,514
|
2,663
|
P/E ratio
|
19.2
x
|
12.9
x
|
11.6
x
|
10.9
x
|
8.84
x
|
7.42
x
|
Yield
|
1.59%
|
-
|
-
|
2.52%
|
2.77%
|
4.2%
|
Capitalization / Revenue
|
4.78
x
|
3.33
x
|
2.12
x
|
1.36
x
|
1.2
x
|
1.07
x
|
EV / Revenue
|
4.38
x
|
3.07
x
|
2.24
x
|
1.49
x
|
1.38
x
|
1.31
x
|
EV / EBITDA
|
12.5
x
|
9.11
x
|
8.37
x
|
7.34
x
|
5.9
x
|
5.21
x
|
EV / FCF
|
1,035
x
|
524
x
|
-269
x
|
7.77
x
|
15
x
|
-85.9
x
|
FCF Yield
|
0.1%
|
0.19%
|
-0.37%
|
12.9%
|
6.68%
|
-1.16%
|
Price to Book
|
-
|
2.57
x
|
-
|
1.02
x
|
0.93
x
|
0.86
x
|
Nbr of stocks (in thousands)
|
179,394
|
177,831
|
177,681
|
177,681
|
-
|
-
|
Reference price
2 |
36.40
|
26.32
|
16.41
|
12.29
|
12.29
|
12.29
|
Announcement Date
|
2/21/22
|
3/1/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,182
|
1,366
|
1,407
|
1,373
|
1,602
|
1,818
|
2,032
|
EBITDA
1 |
-
|
477.5
|
474
|
368
|
326.1
|
426.2
|
511.5
|
EBIT
1 |
-
|
456.6
|
452.2
|
329.3
|
277.5
|
363.9
|
439.9
|
Operating Margin
|
-
|
33.42%
|
32.14%
|
23.99%
|
17.32%
|
20.01%
|
21.65%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
468.6
|
334.2
|
287.2
|
349.8
|
415.6
|
Net income
1 |
-
|
325.2
|
363.4
|
249.8
|
202.9
|
252.6
|
307.4
|
Net margin
|
-
|
23.8%
|
25.83%
|
18.2%
|
12.67%
|
13.89%
|
15.13%
|
EPS
2 |
1.614
|
1.892
|
2.040
|
1.410
|
1.124
|
1.391
|
1.657
|
Free Cash Flow
1 |
-
|
5.78
|
8.232
|
-11.44
|
308
|
168
|
-31
|
FCF margin
|
-
|
0.42%
|
0.59%
|
-0.83%
|
19.22%
|
9.24%
|
-1.53%
|
FCF Conversion (EBITDA)
|
-
|
1.21%
|
1.74%
|
-
|
94.46%
|
39.42%
|
-
|
FCF Conversion (Net income)
|
-
|
1.78%
|
2.27%
|
-
|
151.77%
|
66.51%
|
-
|
Dividend per Share
2 |
-
|
0.5800
|
-
|
-
|
0.3102
|
0.3399
|
0.5165
|
Announcement Date
|
2/5/21
|
2/21/22
|
3/1/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
349.9
|
313.3
|
365.2
|
361.6
|
366.7
|
258.2
|
364.3
|
362.6
|
387.5
|
359.7
|
413.1
|
417.8
|
423.4
|
424.6
|
EBITDA
1 |
91.11
|
115.4
|
120.5
|
119
|
120
|
58
|
94.15
|
163.9
|
52
|
65
|
77.49
|
86.85
|
98.34
|
-
|
EBIT
1 |
-
|
-
|
115.2
|
113.1
|
113.7
|
51.28
|
86.25
|
152.3
|
39.5
|
48.84
|
61.5
|
69.72
|
77.85
|
69.71
|
Operating Margin
|
-
|
-
|
31.55%
|
31.27%
|
31%
|
19.86%
|
23.67%
|
41.98%
|
10.2%
|
13.58%
|
14.89%
|
16.69%
|
18.39%
|
16.42%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
38.02
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-
|
61.46
|
112.4
|
94.53
|
94.98
|
51.95
|
70.79
|
99.4
|
27.68
|
40.09
|
48
|
-
|
-
|
-
|
Net margin
|
-
|
19.61%
|
30.77%
|
26.14%
|
25.9%
|
20.12%
|
19.43%
|
27.41%
|
7.14%
|
11.15%
|
11.62%
|
-
|
-
|
-
|
EPS
2 |
0.2294
|
-
|
0.6300
|
0.4200
|
0.5308
|
-
|
0.4000
|
0.5600
|
0.1600
|
0.2300
|
0.2265
|
0.2695
|
0.3127
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.2805
|
-
|
Announcement Date
|
2/21/22
|
5/9/22
|
8/1/22
|
11/3/22
|
3/1/23
|
5/5/23
|
8/9/23
|
11/9/23
|
3/19/24
|
5/7/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
163
|
210
|
331
|
479
|
Net Cash position
1 |
-
|
548
|
364
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
0.4429
x
|
0.6437
x
|
0.7762
x
|
0.9369
x
|
Free Cash Flow
1 |
-
|
5.78
|
8.23
|
-11.4
|
308
|
168
|
-31
|
ROE (net income / shareholders' equity)
|
-
|
35%
|
21%
|
13.1%
|
9.74%
|
11.1%
|
12.4%
|
ROA (Net income/ Total Assets)
|
-
|
18.1%
|
15.1%
|
9%
|
5.81%
|
6.8%
|
7.32%
|
Assets
1 |
-
|
1,800
|
2,414
|
2,776
|
3,495
|
3,713
|
4,202
|
Book Value Per Share
2 |
-
|
-
|
10.20
|
-
|
12.10
|
13.20
|
14.30
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
148
|
180
|
232
|
102
|
214
|
330
|
Capex / Sales
|
-
|
10.85%
|
12.8%
|
16.9%
|
6.37%
|
11.77%
|
16.24%
|
Announcement Date
|
2/5/21
|
2/21/22
|
3/1/23
|
3/19/24
|
-
|
-
|
-
|
Mean consensus UNDERPERFORM Last Close Price
12.29
BRL Average target price
12.71
BRL Spread / Average Target +3.45% Consensus |
1st Jan change
|
Capi.
|
---|
| -25.11% | 403M | | +61.53% | 848B | | +38.95% | 627B | | -3.66% | 363B | | +15.06% | 318B | | +9.18% | 299B | | +5.89% | 234B | | +16.53% | 225B | | +15.67% | 179B | | +2.47% | 167B |
Other Pharmaceuticals
|